Iovance Shares Down 10% After Licensing Drug From Novartis

Date : 01/13/2020 @ 6:12PM
Source : Dow Jones News
Stock : Iovance Biotherapeutics Inc (IOVA)
Quote : 32.91  -0.12 (-0.36%) @ 11:00PM
After Hours
Last Trade
Last $ 32.91 ◊ 0.00 (0.00%)

Iovance Shares Down 10% After Licensing Drug From Novartis

Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Iovance Biotherapeutics Charts.

By Chris Wack


Iovance Biotherapeutics Inc. (IOVA) shares dropped 10% to $3.65 Monday after the company said it obtained a license from Novartis (NVS) to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001.

The biotechnology company said it will make an up-front payment to Novartis as well as low single digit milestones involved in the initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the product in the U.S., EU and Japan.

Iovance said Novartis also is entitled to low-to-mid single digit royalties from commercial sales of the product.

Iovance said it will focus on manufacturing of IOV-3001 during 2020 and may initiate Investigational New Drug-enabling activities as early as 2021.


Write to Chris Wack at


(END) Dow Jones Newswires

January 13, 2020 12:57 ET (17:57 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest IOVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.